Skip to content

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.: 10-Q/A filed 2020-07-09

What THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. reported in its quarterly report amendment filed 2020-07-09 (fiscal Q1 2020): 34 published measures, 73 facts as tagged in accession 0001078782-20-000532.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2020-07-09
Fiscal period
fiscal Q1 2020
Accession
0001078782-20-000532 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-03-31321,034USD
At 2019-12-31311,001USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-03-312,258,986USD
At 2019-12-312,346,045USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-03-31-1,937,952USD
At 2019-12-31-2,035,044USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-03-313,859USD
At 2019-12-3126,410USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-3132,136USD91
2019-01-01 to 2019-03-31-375,146USD90
2018-01-01 to 2018-03-31-375,146USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-52,066USD91
2019-01-01 to 2019-03-31-106,059USD90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-01-01 to 2020-03-3119,514USD91
2018-01-01 to 2018-03-312,464USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-03-3129,515USD91
2019-01-01 to 2019-03-3184,253USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-03-31-8,800,764USD
At 2019-12-31-8,832,900USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-01-01 to 2020-03-311,621,008,777shares91
2018-01-01 to 2018-03-311,091,073,182shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-01-01 to 2020-03-311,895,283,682shares91
2018-01-01 to 2018-03-311,091,073,182shares90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-01-01 to 2020-03-310USD/shares91
2018-01-01 to 2018-03-310USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-01-01 to 2020-03-310USD/shares91
2018-01-01 to 2018-03-310USD/shares90

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-03-310USD91
2019-01-01 to 2019-03-3150,000USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-122,376USD91
2018-01-01 to 2018-03-31-432,590USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-03-31108,027USD
At 2019-12-31139,679USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-01-01 to 2020-03-3161,135USD91
2018-01-01 to 2018-03-3187,500USD90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-03-312,203,732USD
At 2019-12-312,346,045USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-03-31332,497USD
At 2019-12-31324,936USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-03-313,625USD
At 2019-12-312,904USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-03-31138,400USD91
2018-01-01 to 2018-03-31434,908USD90

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-03-314,488USD
At 2019-12-315,180USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-01-01 to 2020-03-3116,024USD91
2018-01-01 to 2018-03-312,318USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-03-311,656,544,032shares
At 2019-12-311,614,627,811shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-03-3114,046USD
At 2019-12-3136,597USD
At 2019-03-3110,764USD
At 2018-12-3132,570USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-03-315,206,268USD
At 2019-12-315,183,228USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2020-03-31-1,937,952USD
At 2019-12-31-2,035,044USD
At 2019-03-31-1,700,594USD
At 2018-12-31-1,810,468USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2020-03-31946,979USD
At 2019-12-31937,528USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-03-31529,867USD
At 2019-12-31505,072USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-3115,431USD91
2018-01-01 to 2018-03-3113,483USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-01-01 to 2020-03-31154,512USD91
2018-01-01 to 2018-03-3157,444USD90

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-31721USD91
2019-01-01 to 2019-03-311,475USD90

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-692USD91
2019-01-01 to 2019-03-310USD90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-317,562USD91
2019-01-01 to 2019-03-31-2,367USD90

Inspect the source

Entity
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. / CIK 0001419051
Captured
2026-09-21T17:19:45.690Z
SEC response SHA-256
ad44380627053f8e0101ecf19c259e20a0a85d4c20ee53d5400d9dcf00541fc2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001419051.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))